<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968812</url>
  </required_header>
  <id_info>
    <org_study_id>CR016480</org_study_id>
    <secondary_id>28431754DIA3009</secondary_id>
    <secondary_id>2009-009320-36</secondary_id>
    <nct_id>NCT00968812</nct_id>
  </id_info>
  <brief_title>CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride</brief_title>
  <official_title>A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy, safety, and tolerability of
      canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes
      mellitus with inadequate control despite treatment with metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is well recognized as a major public health problem that
      presents patients with a significant risk of complications including heart disease,
      retinopathy, nephropathy, and neuropathy. Various classes of orally administered
      antihyperglycemic agents have been developed for the treatment of diabetes and although
      individual agents may be highly effective for some patients, it is still difficult to
      maintain optimal glycemic control in most patients, thereby resulting in high rates of
      morbidity and mortality in the diabetic population. This is a randomized, double-blind,
      active comparator-controlled, 3-arm, parallel-group, multicenter study to demonstrate the
      efficacy, safety, and tolerability of canagliflozin compared with a sulfonylurea
      (glimepiride) in patients with T2DM, 18 to 80 years of age, inclusive, who are not optimally
      controlled on metformin monotherapy. The primary study hypothesis is that the study drug will
      be non-inferior to glimepiride as assessed by the change in hemoglobin A1c (HbA1c) from
      baseline. The patients will receive capsules taken by mouth of canagliflozin (either 100 or
      300 mg), or glimepiride with a starting dosage of 1 mg, which will be increased to a maximum
      dose of 6 or 8 mg once daily for a total duration of 104 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 52</measure>
    <time_frame>Day 1 (Baseline) and Week 52</time_frame>
    <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52</measure>
    <time_frame>Day 1 (Baseline) and Week 52</time_frame>
    <description>The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 52</measure>
    <time_frame>Day 1 (Baseline) and Week 52</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c From Baseline to Week 104</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1452</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.</description>
    <arm_group_label>Glimepiride</arm_group_label>
    <other_name>sulfonylurea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin (JNJ-28431754)</intervention_name>
    <description>Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.</description>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin will be given orally at the protocol-specified dose for 104 weeks.</description>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of type 2 diabetes

          -  Body mass index (BMI) &gt;=22 to &lt;=45 kg/m2, at screening

          -  Patients must be taking a stable dosage of metformin as monotherapy at screening

          -  Patients must have a HbA1c between &gt;=7% and &lt;=9.5% at Week 2

          -  Patients must have a fasting plasma glucose (FPG) &lt;=270 mg/dL (15 mmol/L) at Week -2

        Exclusion Criteria:

          -  Patients having prior exposure or known contraindication or suspected hypersensitivity
             to JNJ-28431754, glimepiride, or metformin

          -  History of diabetic ketoacidosis or type 1 diabetes mellitus

          -  History of pancreas or beta-cell transplantation

          -  History of active proliferative diabetic retinopathy

          -  History of hereditary glucose-galactose malabsorption or primary renal glucosuria

          -  Renal disease requiring treatment with immunosuppressive therapy within the past 12
             months before screening or a history of dialysis or renal transplant

          -  Taken thiazolidinedione therapy in the past 16 weeks before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Calera</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chipley</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marianna</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldsmar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canal Fulton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gallipolis</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma De Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar Del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dimitrovgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazanlak</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John'S</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Pedro</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vipperoed</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wardha</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad De Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marikina City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasay</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutno 001</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zielona Gora</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubochna</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Portugal</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <results_first_submitted>April 17, 2013</results_first_submitted>
  <results_first_submitted_qc>April 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2013</results_first_posted>
  <disposition_first_submitted>June 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2012</disposition_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Metformin</keyword>
  <keyword>Glimepiride</keyword>
  <keyword>Hemoglobin A1c</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Canagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated the efficacy and safety of canagliflozin (JNJ-28431754) compared with glimepiride in participants with type 2 diabetes mellitus with inadequate glycemic control despite metformin treatment. The study was conducted between 28 August 2009 and 25 January 2013 and included 157 study centers in 19 countries worldwide.</recruitment_details>
      <pre_assignment_details>1,452 participants were randomly allocated to the 3 treatment arms. 1450 participants received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set and safety analysis set. Participant flow is presented for Baseline to Week 104.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Canagliflozin 100 mg: Baseline to Week 104</title>
          <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Canagliflozin 300 mg: Baseline to Week 104</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Glimepiride: Baseline to Week 104</title>
          <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="485"/>
                <participants group_id="P3" count="482"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="343"/>
                <participants group_id="P2" count="323"/>
                <participants group_id="P3" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="168"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Creatinine or eGFR withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to take rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Canagliflozin 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Canagliflozin 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Glimepiride</title>
          <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="483"/>
            <count group_id="B2" value="485"/>
            <count group_id="B3" value="482"/>
            <count group_id="B4" value="1450"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="397"/>
                    <measurement group_id="B2" value="411"/>
                    <measurement group_id="B3" value="399"/>
                    <measurement group_id="B4" value="1207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="9.49"/>
                    <measurement group_id="B2" value="55.8" spread="9.17"/>
                    <measurement group_id="B3" value="56.3" spread="9.01"/>
                    <measurement group_id="B4" value="56.2" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="219"/>
                    <measurement group_id="B4" value="694"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="263"/>
                    <measurement group_id="B4" value="756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region Enroll</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ARGENTINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BULGARIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COSTA RICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENMARK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FINLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISRAEL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NORWAY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHILIPPINES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUSSIAN FEDERATION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLOVAKIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH KOREA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKRAINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 52</title>
        <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 52</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 52 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 52</title>
          <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 52 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="474"/>
                <count group_id="O3" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.039"/>
                    <measurement group_id="O2" value="-0.93" spread="0.039"/>
                    <measurement group_id="O3" value="-0.81" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>If the hypothesis of non-inferiority of canagliflozin to glimepiride at Week 52 was demonstrated (ie, upper bound of the 95% Confidence Interval of the treatment difference [canagliflozin minus glimepiride] was less than 0.3) and the upper bound was less than 0.0, the superiority of the canagliflozin dose relative to glimepiride would be concluded.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculation: assuming a difference between canagliflozin and glimepiride of 0.0% and a common standard deviation of 1.0%, and using a 2-sample, 1-sided t-test with a Type I error rate of 0.0125, and assuming a drop-out rate of 35% in 52 weeks, it was estimated that approximately 427 patients per group would provide 90% power to demonstrate non-inferiority with the non-inferiority margin of 0.3, comparing canagliflozin with glimepiride.</non_inferiority_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.109</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>If the hypothesis of non-inferiority of canagliflozin to glimepiride at Week 52 was demonstrated (ie, upper bound of the 95% Confidence Interval of the treatment difference [canagliflozin minus glimepiride] was less than 0.3) and the upper bound was less than 0.0, the superiority of the canagliflozin dose relative to glimepiride would be concluded.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Power calculation: assuming a difference between canagliflozin and glimepiride of 0.0% and a common standard deviation of 1.0%, and using a 2-sample, 1-sided t-test with a Type I error rate of 0.0125, and assuming a drop-out rate of 35% in 52 weeks, it was estimated that approximately 427 patients per group would provide 90% power to demonstrate non-inferiority with the non-inferiority margin of 0.3, comparing canagliflozin with glimepiride</non_inferiority_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.217</ci_lower_limit>
            <ci_upper_limit>-0.023</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52</title>
        <description>The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages.</description>
        <time_frame>Day 1 (Baseline) and Week 52</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 52 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52</title>
          <description>The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 52 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="485"/>
                <count group_id="O3" value="482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 52</title>
        <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 52</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 52 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 52</title>
          <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 52 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="0.2"/>
                    <measurement group_id="O2" value="-4.7" spread="0.2"/>
                    <measurement group_id="O3" value="1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-5.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>-4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-5.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c From Baseline to Week 104</title>
        <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 104</title>
          <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug).</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="474"/>
                <count group_id="O3" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.042" lower_limit="0.10" upper_limit="0.22"/>
                    <measurement group_id="O2" value="-0.74" spread="0.042" lower_limit="0.10" upper_limit="0.21"/>
                    <measurement group_id="O3" value="-0.55" spread="0.043" lower_limit="0.31" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.200</ci_lower_limit>
            <ci_upper_limit>0.010</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.289</ci_lower_limit>
            <ci_upper_limit>-0.078</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the duration of the study (104 weeks).</time_frame>
      <desc>The total number of adverse events listed in the &quot;Other (non-Serious) Adverse Events&quot; table are based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any treatment arm.
MEDDRA 14.1 used for Week 52 / MEDDRA 15.0 for Week 104 results.</desc>
      <group_list>
        <group group_id="E1">
          <title>Canagliflozin 100 mg: Baseline to Week 52</title>
          <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E2">
          <title>Canagliflozin 300 mg: Baseline to Week 52</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E3">
          <title>Glimepiride: Baseline to Week 52</title>
          <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E4">
          <title>Canagliflozin 100 mg: Baseline to Week 104</title>
          <description>Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks. Data are presented for Baseline to Week 104.</description>
        </group>
        <group group_id="E5">
          <title>Canagliflozin 300 mg: Baseline to Week 104</title>
          <description>Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks. Data are presented for Baseline to Week 104.</description>
        </group>
        <group group_id="E6">
          <title>Glimepiride: Baseline to Week 104</title>
          <description>Each patient received glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks. Data are presented for Baseline to Week 104.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.1 / 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="69" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Diabetic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arnold-Chiari malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Philmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <description>This event was re-coded as &quot;Small bowel perforation&quot;; it was subsequently re-mapped to the &quot;Surgical and medical procedures&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated herina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <description>In the Week 52 study report, this event was coded as &quot;infection&quot;; it was subsequently re-coded in the Week 104 study report as &quot;localised infection&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>In the Week 52 study report, this event was coded as &quot;infection&quot;; it was subsequently re-coded in the Week 104 study report as &quot;localised infection&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave biphasic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Renal cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Breast cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid arterial embolus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hemiplegic migraine</sub_title>
                <description>In the Week 52 study report, this event was coded as &quot;Hemiplegic migraine&quot;; it was subsequently re-coded in the Week 104 study report as &quot;Hemiparesis&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <description>In the Week 52 study report, this event was coded as &quot;Hemiplegic migraine&quot;; it was subsequently re-coded in the Week 104 study report as &quot;Hemiparesis&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <description>In the Week 52 study report, this event was coded as &quot;stress&quot;; it was subsequently re-coded in the Week 104 study report as &quot;anxiety&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>In the Week 52 study report, this event was coded as &quot;stress&quot;; it was subsequently re-coded in the Week 104 study report as &quot;anxiety&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Familial risk factor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Small bowel perforation</sub_title>
                <description>In Week 52 study report this event was coded as &quot;small intestinal perforation&quot; and was mapped under &quot;Gastrointestinal disorders &quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title vocab="MEDDRA 14.1">Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1 / 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="198" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="204" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="242" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="482"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="56" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="86" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="482"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="485"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="482"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="483"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="485"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="482"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No notable study limitations were identified by the Sponsor.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President, Franchise Medical Leader, Cardiovascular &amp; Metabolism Franchise</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>1-800-526-7736</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

